查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1853778

新冠病毒檢測市場按檢測類型、樣本類型和最終用戶分類－2025-2032年全球預測

COVID-19 Testing Market by Test Type, Sample Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，COVID-19 檢測市場規模將成長 952 億美元，複合年成長率為 10.56%。

關鍵市場統計數據
基準年2024年 426.2億美元
預計年份：2025年 471.3億美元
預測年份 2032 952億美元
複合年成長率 (%) 10.56%

對不斷變化的 COVID-19 檢測格局進行清晰概述，以明確診斷選擇、操作權衡和相關人員的策略決策槓桿。

由於科學進步、公共衛生重點的轉變以及全球供應鏈的變化，新冠病毒檢測模式仍在快速演變。本執行摘要摘要診斷方法的技術進步與監管調整、供應彈性以及分散式檢查模式的普及等實際操作情況進行了梳理。

相關人員必須權衡檢測的臨床效能特徵與實際考慮因素，例如周轉時間、易用性和檢體類型相容性。這種平衡將決定檢測的採用模式以及最適合特定應用情境（從醫院分診到居家監測）的檢測路徑。更先進的分子技術的應用和基於抗原的快速檢測的標準化，既補充又挑戰了傳統實驗室PCR檢測的核心地位，迫使各機構重新思考其工作流程、人員配置模式和投資重點。

最後，引言部分概述了報告著重於可操作資訊的重點。報告著重闡述了能夠幫助領導者應對採購複雜性、最佳化檢測組合以及使診斷策略與更廣泛的公共衛生和商業性目標一致的洞見。接下來的內容強調實際應用，而非不切實際的推斷，從而為在診斷領域不斷成熟的過程中做出穩健且基於證據的決策奠定基礎。

快速的技術創新、分散式醫療保健路徑和靈活的監管如何從根本上改變診斷服務模式和策略重點

技術創新、去中心化和監管靈活性正在以既顛覆又賦能的方式重塑診斷格局，尤其體現在更靈敏、多重化的分子檢測和易於操作的快速抗原檢測方法上。這些創新催生了一種新的創造性模式：檢測不再是中心實驗室的專屬領域；即時檢測和居家檢測在早期發現、治療分診和社區監測中發揮著越來越重要的作用。

同時，政策轉變鼓勵加速法規核准流程和採用更靈活的報銷機制，加速市場准入，同時也提高了上市後績效監測的標準。因此，製造商、服務供應商和醫療系統必須建立更具活力的生態系統才能保持競爭力。投資多元化採購、靈活生產和垂直整合試劑管線的公司，更有能力應對突如其來的需求激增或原料短缺。

隨著市場格局的演變，能夠將產品創新與以用戶為中心的部署模式相結合、加強診斷價值鏈各環節的夥伴關係、並將真實世界的性能反饋融入產品開發的企業，將成為未來的贏家。這項轉變要求研發、監管、採購和商業團隊通力合作、精心規劃，在管控營運風險的同時，掌握新的機遇，創造價值。

檢驗不斷變化的貿易政策如何重塑診斷檢測生態系統的籌資策略、生產選擇和採購慣例。

美國關稅調整和貿易政策行動將對新冠病毒檢測價值鏈產生重大影響，進而影響診斷耗材的相對成本、供應和分銷。對關鍵零件徵收更高的進口關稅可能會增加檢測試劑生產商和檢測套組組裝商的投入成本，從而擠壓利潤空間或迫使採購商將成本轉嫁給消費者。除了影響單價外，關稅還可能改變採購策略，促使供應商進行地理多元化，並重新聚焦本地生產能力，以保護診斷必需品免受國際貿易波動的影響。

累積影響也將波及供應鏈的時序安排和庫存策略。為因應關稅帶來的不確定性，各組織將擴大常用試劑和耗材的安全庫存，與一級主導談判長期契約，並尋找替代零件來源。雖然這些措施可能緩解眼前的供應風險，但也可能導致營運成本需求和倉儲成本增加。同時，原料和零件製造商可能會加快投資，將部分生產環節轉移到國內或免稅地區，並重組其供應商格局和夥伴關係關係。

採購機構和衛生系統的政策應對措施通常是加強支持國內生產，具體措施包括有針對性的優先採購、提前承諾採購以及獎勵設施升級。決策者的策略重點是製定靈活的採購框架，檢驗來自多個管道的供應，並進行基於情境的規劃，以因應貿易中斷和監管環境的變化。這種準備工作有助於降低營運脆弱性，並在各種貿易制度下維持檢測服務的連續性。

主導細分市場，清楚闡明檢測方式、檢體選擇和最終使用者管道如何相互交織，從而決定診斷效用和操作可行性。

對市場區隔的深入理解有助於明確投資和營運改善的重點領域。從檢測類型來看，市場涵蓋抗體檢測、抗原檢測和即時PCR檢測，其中即時PCR檢測又因數位PCR、多重PCR和定量PCR等技術的進步而進一步細分。抗體檢測可用於血清陽性率和回顧性暴露分析，抗原檢測可實現快速照護現場，而各種PCR檢測則可用於診斷確認、病毒量評估和多重病原體檢測。

雖然血液檢測是獲取血清學資訊的常用方法，但樣本基質的選擇會進一步影響檢測方案的製定，因為鼻咽拭子、口咽拭子和唾液樣本在靈敏度、患者舒適度和採集物流等方面各有優劣。樣本類型的選擇會影響臨床工作流程、檢體運輸要求和生物安全通訊協定，因此，根據特定應用情境進行仔細選擇至關重要。

診斷實驗室強調高通量、高度可控的環境；家庭使用反映了消費者主導的檢測和自採集模式的興起；醫院和診所優先考慮能夠指導即時治療決策的快速診斷結果；而研究機構則致力於檢測方法的檢驗、變異監測和方法創新。了解檢測類型與樣本類型和最終用戶的對應關係，將有助於揭示診斷效用、報銷潛力和操作可行性之間的交集，從而使相關人員能夠設計出滿足臨床需求和使用者能力的產品。

區域差異化分析表明，基礎設施、監管和製造業優勢如何影響全球檢測通道的准入和營運策略。

區域動態正在影響新冠病毒檢測的取得、應用和運作方式，各主要區域已呈現明顯的趨勢。在美洲，診斷網路優先考慮規模和容量，透過整合實驗室服務和強大的檢測能力，支持分子檢測和抗原檢測平台的廣泛部署。法規環境正朝著快速緊急核准和合理的報銷安排方向發展，這不僅加速了創新檢測方式的推廣，也要求強力的品質保證以維護臨床信心。

由於衛生系統成熟度和採購能力的差異，歐洲、中東和非洲的情況各不相同。高所得的歐洲市場擁有嚴格的法律規範和強大的實驗室基礎設施，能夠進行先進的分子檢測和集中定序，從而追蹤病毒變異。相反，該地區許多中低收入國家則優先考慮成本效益高的抗原檢測和混合檢測策略，以擴大檢測覆蓋範圍。跨國合作和多邊採購機制在緩解供應不平衡和加速資源匱乏地區獲得檢測方面可以發揮重要作用。

亞太地區展現出快速創新和製造業實力的頻譜。該地區多個經濟體擁有強大的試劑、套件和儀器生產能力，既支持國內市場，也支持出口導向供應鏈。許多區域政策制定者正在推動儘早採用分散式檢查模式，並投資於數位整合，以簡化報告流程和公共衛生應對措施。綜上所述，這些區域差異需要製定量身定做的商業化、監管和供應策略，以反映當地的基礎設施、支付模式和公共衛生優先事項。

深入了解競爭定位、夥伴關係和能力投資，這些因素共同造就了診斷創新和供應鏈可靠性領域的領導者。

新冠病毒檢測領域的競爭格局呈現出快速的產品創新、策略夥伴關係以及圍繞核心競爭力的整合浪潮。領先企業正投資於兼具強大分析效能、易用性、穩健的供應鏈網路以及與醫療系統整合的數據報告功能的診斷平台。試劑供應商、儀器製造商和實驗室網路之間的合作正在加速新檢測方法的上市，並提高分銷效率；同時，與物流和低溫運輸供應商的夥伴關係正在解決「最後一公里」配送難題。

對品質系統和上市後監測的投資已成為維護聲譽和遵守監管規定的必然要求，促使企業加強臨床檢驗項目和實際應用性能監測。能夠展現出持續可靠的營運能力和透明的檢測性能數據的企業更有可能贏得醫療系統和公共機構的採購合約。此外，那些專注於模組化設計以實現檢測升級、多重檢測能力和數位化連接的企業，能夠更好地適應不斷湧現的新變體和不斷變化的臨床需求。

產業參與者的一項策略重點是協調研發、供應鏈韌性和商業性執行。建立可擴展的製造地、實現供應商多元化以及提供靈活的商業模式（例如訂閱測試服務和試劑即服務協議）可以幫助企業與客戶建立長期合作關係，並緩解週期性需求波動。

診斷設備製造商和服務供應商可採取的切實可行的策略重點，以建立具有韌性的供應鏈、模組化產品和以客戶為中心的交付模式。

產業領導者應採取多管齊下的策略，並專注於具有韌性的供應鏈、模組化產品設計和數據驅動的服務交付。優先考慮關鍵投入來源多元化，並制定包含合格替代供應商和本地生產能力的緊急時應對計畫，以降低貿易中斷帶來的風險。將供應鏈壓力測試納入日常規劃週期，保持對上游供應商網路的可見性，並在瓶頸影響交貨之前預先發現並解決它們。

同時，我們將投資於適應性強的產品架構：設計可針對新標靶進行更新、支援多重檢測並與數位化彙報系統對接的檢測方法和平台。這種適應性將有助於實現面向未來的成本節約，並延長已部署設備的使用壽命。我們將與臨床實驗室和醫療系統建立夥伴關係關係，共同開發最佳化集中式和分散式檢測部署流程的工作流程，確保在適當的場景下提供適當的檢測。

最後，透過調整定價和合約模式以適應客戶需求、提供靈活的購買條款以及捆綁分析服務，可以增強商業化能力。加強上市後監測和真實世界證據項目，有助於建立信任並展現持續的業績表現。將營運韌性、產品敏捷性和以客戶為中心的商業性模式結合，產業領導者既可以抓住成長機遇，又能保障服務的連續性。

我們的調查方法結合了專家諮詢、文件分析和情境測試，旨在提供可靠且以決策為導向的診斷見解。

本研究整合了一手和二手資料，旨在得出專注於實際應用而非推測性預測的見解。一手資料包括與實驗室主任、採購負責人和臨床營運負責人進行的結構化討論，以及與供應鏈經理和產品開發主管進行的針對性訪談。這些討論得出了關於營運優先事項、產品性能權衡以及壓力條件下採購行為的定性評估。

二次分析利用同儕審查文獻、監管指導文件和公共衛生機構發布的資料，檢驗技術性能聲明並分析政策動態。透過交叉引用多個資訊來源，可以對關鍵主題進行三角驗證，尤其是在檢測靈敏度權衡、不同樣本類型性能差異以及應對供應挑戰的政策措施等領域。資料解讀優先考慮可重複性和透明度，調查方法和資料來源的標準已記錄在報告的附錄中。

研究採用情境建模方法，對供應鏈和採購應對政策中斷的反應進行壓力測試，並進行敏感度分析，探索可能出現的其他結果。調查方法盡可能強調可追溯的證據和專家佐證，以確保研究結果的可靠性，並能為尋求實施診斷策略的決策者提供實際參考。

綜合各項結論，重點闡述永續診斷策略、彈性運作以及將數位技術與商業性創新結合以實現長期價值的重要性。

新冠病毒檢測生態系統已從緊急應變階段發展到結構成熟階段，其特徵是技術不斷完善、供應鏈管理策略穩健、監管規範日益完善。現今的診斷策略需要採取平衡的方法，使檢測方法的選擇與臨床需求相符，制定穩健的採購和生產計劃，並將實際性能監測納入生命週期管理。決策者必須持續評估平台能力與實際營運狀況的匹配度，確保投資能夠支援永續的服務交付，而非僅僅滿足短期需求高峰。

展望未來，整合診斷和數位化彙報系統並提供靈活的商業性安排的能力將成為市場領導者的標誌。同樣，投資於適應性檢測設計和多元化製造地的企業將更有能力應對政策變化和供應鏈中斷。最終，成功邁入下一階段的檢測，取決於臨床、商業和營運部門之間的協調規劃，並以實證方法和切合實際的風險管理為基礎。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在農村和低度開發地區擴大快速家用抗原檢測的使用
  • 整合多重呼吸道病原體檢測板，用於同時檢測新冠病毒和其他病原體
  • 拓展人工智慧驅動的診斷分析，以最大限度地減少RT-PCR新冠病毒檢測中的假陰性結果
  • 大型集會場所對移動式PCR檢測車的需求激增，以便提供快速、現場的COVID-19檢測結果。
  • 高靈敏度唾液診斷技術的出現，使得在學校進行非侵入性新冠病毒篩檢成為可能。
  • 診斷公司與遠端醫療平台夥伴關係，實現無縫的遠距新冠病毒檢測工作流程

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依檢測類型分類的 COVID-19 檢測市場

  • 抗體檢測
  • 抗原檢測
  • 即時PCR檢測
    • 數位PCR
    • 多重PCR
    • 定量PCR

9. 依樣本類型分類的 COVID-19 檢測市場

  • 血
  • 鼻咽拭子
  • 口咽拭子
  • 唾液

第10章：按最終用戶分類的 COVID-19 檢測市場

  • 診斷實驗室
  • 家用
  • 醫院和診所
  • 研究機構

第11章：各地區的 COVID-19 檢測市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：按群體分類的新冠病毒檢測市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：各國新冠病毒檢測市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche AG
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • Becton, Dickinson and Company
    • QIAGEN NV
    • Hologic, Inc.
    • bioMerieux SA
    • PerkinElmer, Inc.
    • Siemens Healthineers AG
Product Code: MRR-02026C4C986E

The COVID-19 Testing Market is projected to grow by USD 95.20 billion at a CAGR of 10.56% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 42.62 billion
Estimated Year [2025] USD 47.13 billion
Forecast Year [2032] USD 95.20 billion
CAGR (%) 10.56%

An incisive overview of the evolving COVID-19 testing environment that clarifies diagnostic choices, operational trade-offs, and strategic decision levers for stakeholders

The COVID-19 testing environment continues to evolve at pace, shaped by scientific advances, shifting public health priorities, and changes across global supply chains. This executive summary synthesizes the most salient developments that inform decision-making for clinical laboratories, manufacturers, policy makers, and procurement teams. It frames the technical progress in diagnostic modalities alongside operational realities-regulatory adaptation, supply resilience, and the diffusion of decentralized testing models-that together define how testing is delivered and valued in clinical and community settings.

Across settings, stakeholders must weigh the clinical performance characteristics of assays against practical considerations such as turnaround time, ease of use, and sample type compatibility. This balance drives adoption patterns and determines which testing pathways are best suited to specific use cases, from hospital triage to at-home surveillance. The introduction of more refined molecular techniques and the normalization of antigen-based rapid testing have both complemented and contested the central role of traditional laboratory-based PCR, prompting organizations to reassess workflows, staffing models, and investment priorities.

Finally, the introduction outlines how this report focuses on actionable intelligence. It prioritizes insights that help leaders navigate procurement complexity, optimize testing portfolios, and align diagnostic strategies with broader public health and commercial objectives. The content that follows emphasizes practical implications rather than raw estimates, offering a foundation for resilient, evidence-based decision-making as the diagnostic landscape continues to mature.

How rapid technological innovation, decentralized care pathways, and regulatory agility are fundamentally transforming diagnostic delivery models and strategic priorities

Innovation, decentralization, and regulatory flexibility have collectively reshaped the diagnostic landscape in ways that are both disruptive and enabling. Technological advances have expanded the toolkit available to clinicians and consumers, notably through more sensitive and multiplexed molecular assays as well as rapid antigen formats optimized for ease of administration. These innovations have created new operational paradigms: testing is no longer the exclusive domain of centralized laboratories, and point-of-care or at-home testing increasingly contributes to early detection, therapeutics triage, and community surveillance.

Concurrently, policy shifts have encouraged faster regulatory pathways and adaptive reimbursement structures, which accelerates market entry while raising the bar for post-market performance monitoring. The net effect is a more dynamic ecosystem in which manufacturers, service providers, and health systems must iterate rapidly to maintain relevance. Supply chain sophistication has become a strategic differentiator; organizations that invest in diversified sourcing, flexible manufacturing, and vertically integrated reagent pipelines are better positioned to respond to sudden demand surges or material bottlenecks.

As the landscape transforms, the winners will be those that align product innovation with user-centered deployment models, strengthen partnerships across the diagnostic value chain, and embed real-world performance feedback into product development. These shifts require coordinated planning across R&D, regulatory, procurement, and commercial teams to capture value from emerging opportunities while managing operational risk.

Examining how evolving trade measures are reshaping sourcing strategies, manufacturing choices, and procurement practices across the diagnostic testing ecosystem

Tariff changes and trade policy measures in the United States have material implications for the COVID-19 testing value chain, influencing the relative cost, availability, and distribution of diagnostic supplies. Increased import duties on critical components can raise input costs for assay manufacturers and test kit assemblers, which in turn places pressure on margins or necessitates cost pass-throughs for purchasers. Beyond unit cost effects, tariffs alter procurement calculus by incentivizing regional diversification of suppliers and renewed emphasis on local manufacturing capabilities to shield essential diagnostics from international trade volatility.

The cumulative impact extends to supply chain timing and inventory strategies. Organizations respond to tariff-driven uncertainty by expanding safety stocks of high-use reagents and consumables, negotiating longer-term contracts with tier-one suppliers, and qualifying alternative component sources. These responses can mitigate immediate availability risks but also increase working capital requirements and warehousing overhead. Concurrently, raw material and component manufacturers may accelerate investments to move certain stages of production onshore or to tariff-exempt jurisdictions, reshaping supplier landscapes and partnership structures.

Policy reaction from procurement authorities and health systems often includes a greater willingness to support domestic production through targeted procurement preference, advance purchase commitments, or incentives for facility upgrades. For decision-makers, the strategic focus should be on building flexible sourcing frameworks, validating multi-sourced supply streams, and engaging in scenario-based planning that anticipates both trade disruptions and shifting regulatory conditions. Such preparedness reduces operational fragility and preserves continuity of testing services under varied trade regimes.

Segment-driven clarity on how test modalities, specimen choices, and end-user channels intersect to determine diagnostic utility and operational feasibility

A nuanced understanding of segmentation informs where investments and operational enhancements deliver the greatest impact. When viewed through the lens of test type, the market spans antibody testing, antigen testing, and Real Time PCR testing, with Real Time PCR further differentiated by advances such as Digital PCR, Multiplex PCR, and Quantitative PCR. Each modality carries distinct performance and operational profiles: antibody assays support seroprevalence and retrospective exposure analyses, antigen tests enable rapid point-of-care screening, and the various forms of PCR serve diagnostic confirmation, viral load assessment, and multiplexed pathogen detection.

Sample matrix selection further refines deployment decisions, as blood-based assays are typically leveraged for serological insights while nasopharyngeal swabs, oropharyngeal swabs, and saliva each present trade-offs between sensitivity, patient comfort, and collection logistics. The choice of sample type influences clinical workflows, specimen transport requirements, and biosafety protocols, and therefore merits careful alignment with intended use cases.

End-user channels complete the segmentation picture: diagnostic laboratories focus on high-throughput, highly controlled environments; home use reflects the rise of consumer-directed testing and self-collection models; hospitals and clinics prioritize rapid diagnostic turnarounds that inform immediate care decisions; and research institutes drive assay validation, variant surveillance, and methodological innovation. Understanding how test types map to sample types and end users clarifies where diagnostic utility, reimbursement potential, and operational feasibility converge, enabling stakeholders to design offerings that match clinical demands and user capabilities.

A regionally differentiated analysis showing how infrastructure, regulation, and manufacturing strengths shape testing access and operational strategies across global corridors

Regional dynamics shape access, adoption, and operational approaches to COVID-19 testing, with distinct trends emerging across major geographies. In the Americas, diagnostic networks emphasize scale and throughput, with consolidated laboratory services and substantial testing capacity that supports wide deployment of both molecular and antigen platforms. The regulatory environment tends to favor rapid emergency authorizations and pragmatic reimbursement arrangements, which accelerates adoption of innovative testing formats while also necessitating robust quality assurance to maintain clinical reliability.

In Europe, Middle East & Africa, diverse health system maturity levels and procurement capacities lead to a heterogeneous landscape. High-income European markets combine stringent regulatory oversight with strong laboratory infrastructure, enabling advanced molecular applications and centralized sequencing for variant tracking. Conversely, many middle- and low-income countries within the broader region prioritize cost-effective antigen testing and pooled testing strategies to expand coverage. Cross-border collaboration and multilateral procurement mechanisms play an important role in smoothing supply imbalances and accelerating access in resource-constrained settings.

Asia-Pacific presents a spectrum of rapid innovation and manufacturing strength. Several economies in the region possess significant production capacity for reagents, kits, and instrumentation, which supports export-oriented supply chains as well as domestic deployment. Policymakers in many jurisdictions have promoted early adoption of decentralized testing models and invested in digital integration to streamline reporting and public health responses. Taken together, regional nuances demand tailored commercialization, regulatory, and supply strategies that reflect local infrastructure, payer models, and public health priorities.

Insights into competitive positioning, partnership architectures, and capability investments that define leaders in diagnostic innovation and supply reliability

Competitive dynamics within the COVID-19 testing sector are characterized by rapid product innovation, strategic partnerships, and a wave of consolidation around core capabilities. Leading organizations are investing in diagnostics platforms that combine strong analytical performance with ease of use, robust supply networks, and integrated data reporting to health systems. Collaboration between reagent suppliers, instrument manufacturers, and laboratory networks accelerates time-to-market for new assays and enhances distribution efficiency, while partnerships with logistics and cold-chain providers address last-mile delivery challenges.

Investment in quality systems and post-market surveillance has become a reputational and regulatory imperative, prompting companies to strengthen clinical validation programs and real-world performance monitoring. Firms that demonstrate consistent operational reliability and transparent data on test performance are more successful at securing procurement contracts with healthcare systems and public agencies. Additionally, firms focused on modularity-enabling assay upgrades, multiplexing capabilities, and digital connectivity-are better positioned to adapt to variant emergence and evolving clinical needs.

For industry participants, the strategic priority is to align R&D, supply chain resilience, and commercial execution. Building scalable manufacturing footprints, diversifying supplier bases, and offering flexible commercial models such as subscription testing services or reagent-as-a-service agreements help firms capture long-term relationships with customers and mitigate cyclical demand fluctuations.

Actionable strategic priorities for diagnostic manufacturers and service providers to build resilient supply chains, modular products, and customer-centric delivery models

Industry leaders should adopt a multi-dimensional strategy that emphasizes resilient supply chains, modular product design, and data-enabled service offerings. Prioritize diversification of critical input sources and develop contingency plans that include qualified alternative suppliers and localized production capacity to reduce exposure to trade disruptions. Integrate supply chain stress testing into routine planning cycles and maintain visibility across the upstream supplier network to anticipate bottlenecks before they impact delivery.

In parallel, invest in product architectures that are adaptable-design assays and platforms that can be updated for new targets, support multiplexing, and interface with digital reporting systems. This adaptability lowers the cost of future-proofing and increases the lifespan of deployed instruments. Embrace partnerships with clinical laboratories and health systems to co-develop workflows that optimize test placement between centralized and decentralized settings, ensuring the right test is delivered in the right context.

Finally, enhance commercialization by aligning pricing and contracting models with customer needs, offering flexible purchasing terms, and bundling analytic services. Strengthen post-market surveillance and real-world evidence programs to build trust and demonstrate sustained performance. By combining operational resilience with product agility and customer-centric commercial approaches, industry leaders can capture growth opportunities while safeguarding service continuity.

Methodological approach combining expert consultation, documentary analysis, and scenario testing to produce robust, decision-oriented diagnostic insights

This research synthesizes primary and secondary intelligence to produce insights that emphasize practical implications over speculative projections. Primary inputs included structured consultations with laboratory directors, procurement officers, and clinical affairs leaders, together with targeted interviews of supply chain managers and product development executives. These discussions informed qualitative assessments of operational priorities, product performance trade-offs, and procurement behaviors under stress conditions.

Secondary analysis drew upon peer-reviewed literature, regulatory guidance documents, and public health agency releases to validate technical performance claims and to contextualize policy dynamics. Cross-referencing multiple sources enabled triangulation of key themes, particularly in areas such as assay sensitivity trade-offs, sample type performance nuances, and policy responses to supply challenges. Data interpretation prioritized reproducibility and transparency, with methodological notes and criteria for source inclusion documented in the full report annex.

The study used scenario-based modeling to stress test supply chain and procurement responses to policy disruptions, with sensitivity analyses that explore plausible alternative outcomes. Wherever possible, the methodology emphasized traceable evidence and expert corroboration to ensure findings are robust and practically relevant for decision-makers seeking to operationalize diagnostic strategies.

Concluding synthesis emphasizing sustainable diagnostic strategies, resilient operations, and the integration of digital and commercial innovations for long-term value

The COVID-19 testing ecosystem has moved from emergency improvisation to structured maturation, defined by technological refinement, strategic supply chain management, and evolving regulatory norms. Diagnostic strategies now require a balanced approach that matches assay selection to clinical purpose, incorporates resilient sourcing and manufacturing planning, and embeds real-world performance monitoring into lifecycle management. Decision-makers must continually reassess the alignment between platform capabilities and operational realities, ensuring that investments support sustainable service delivery rather than short-term demand spikes.

Looking ahead, the capacity to integrate diagnostics with digital reporting systems and to offer flexible commercial arrangements will distinguish market leaders. Likewise, organizations that invest in adaptable assay designs and diversified manufacturing footprints will be better positioned to manage policy changes and supply interruptions. Ultimately, successful navigation of the next phase of the testing landscape will depend on coordinated planning across clinical, commercial, and operational functions, underpinned by evidence-based approaches and pragmatic risk management.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of at-home rapid antigen test adoption among rural and underserved communities
  • 5.2. Integration of multiplex respiratory panels for simultaneous detection of COVID-19 and other pathogens
  • 5.3. Scaling of AI-driven diagnostic analytics to minimize false negatives in RT-PCR COVID-19 assays
  • 5.4. Surge in demand for mobile PCR testing units providing rapid on-site COVID-19 results at mass gatherings
  • 5.5. Emergence of high-sensitivity saliva-based diagnostics enabling non-invasive COVID-19 screening in schools
  • 5.6. Partnerships between diagnostic companies and telehealth platforms driving seamless remote COVID-19 testing workflows
  • 5.7. Introduction of CRISPR-based point-of-care assays offering sub-30-minute COVID-19 variant identification in clinics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. COVID-19 Testing Market, by Test Type

  • 8.1. Antibody Test
  • 8.2. Antigen Test
  • 8.3. Real Time Pcr Test
    • 8.3.1. Digital Pcr
    • 8.3.2. Multiplex Pcr
    • 8.3.3. Quantitative Pcr

9. COVID-19 Testing Market, by Sample Type

  • 9.1. Blood
  • 9.2. Nasopharyngeal Swab
  • 9.3. Oropharyngeal Swab
  • 9.4. Saliva

10. COVID-19 Testing Market, by End User

  • 10.1. Diagnostic Laboratories
  • 10.2. Home Use
  • 10.3. Hospitals And Clinics
  • 10.4. Research Institutes

11. COVID-19 Testing Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. COVID-19 Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. COVID-19 Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. F. Hoffmann-La Roche AG
    • 14.3.2. Abbott Laboratories
    • 14.3.3. Thermo Fisher Scientific Inc.
    • 14.3.4. Danaher Corporation
    • 14.3.5. Becton, Dickinson and Company
    • 14.3.6. QIAGEN N.V.
    • 14.3.7. Hologic, Inc.
    • 14.3.8. bioMerieux SA
    • 14.3.9. PerkinElmer, Inc.
    • 14.3.10. Siemens Healthineers AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. COVID-19 TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. COVID-19 TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COVID-19 TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COVID-19 TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COVID-19 TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIBODY TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COVID-19 TESTING MARKET SIZE, BY ANTIGEN TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COVID-19 TESTING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COVID-19 TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COVID-19 TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COVID-19 TESTING MARKET SIZE, BY NASOPHARYNGEAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COVID-19 TESTING MARKET SIZE, BY OROPHARYNGEAL SWAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COVID-19 TESTING MARKET SIZE, BY SALIVA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COVID-19 TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOME USE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COVID-19 TESTING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COVID-19 TESTING MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COVID-19 TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. AMERICAS COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 101. AMERICAS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. AMERICAS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 105. AMERICAS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. AMERICAS COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 114. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 116. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. NORTH AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 124. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 128. LATIN AMERICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 139. EUROPE COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. EUROPE COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 142. EUROPE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 143. EUROPE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 144. EUROPE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 145. EUROPE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. EUROPE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 147. EUROPE COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. EUROPE COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 154. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. MIDDLE EAST COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. AFRICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. AFRICA COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AFRICA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 164. AFRICA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 165. AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. AFRICA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 168. AFRICA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL COVID-19 TESTING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. ASEAN COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. ASEAN COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. ASEAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. ASEAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 186. ASEAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 187. ASEAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. ASEAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. ASEAN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. ASEAN COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. GCC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GCC COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GCC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. GCC COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. GCC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 196. GCC COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 197. GCC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. GCC COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. GCC COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 200. GCC COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPEAN UNION COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. BRICS COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. BRICS COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. BRICS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. BRICS COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. BRICS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 216. BRICS COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 217. BRICS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. BRICS COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. BRICS COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. BRICS COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. G7 COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. G7 COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. G7 COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. G7 COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. G7 COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 226. G7 COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 227. G7 COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. G7 COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. G7 COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. G7 COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NATO COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 232. NATO COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 233. NATO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. NATO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. NATO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 236. NATO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 237. NATO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. NATO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. NATO COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 240. NATO COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL COVID-19 TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. UNITED STATES COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. UNITED STATES COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. UNITED STATES COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED STATES COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 247. UNITED STATES COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED STATES COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. UNITED STATES COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED STATES COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. CANADA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. CANADA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. CANADA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 254. CANADA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 255. CANADA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. CANADA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. CANADA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. CANADA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. MEXICO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. MEXICO COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 261. MEXICO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 262. MEXICO COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 263. MEXICO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. MEXICO COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. MEXICO COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. MEXICO COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. BRAZIL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. BRAZIL COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. BRAZIL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 270. BRAZIL COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 271. BRAZIL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. BRAZIL COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. BRAZIL COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. BRAZIL COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 278. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 279. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. UNITED KINGDOM COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. GERMANY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. GERMANY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 286. GERMANY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 287. GERMANY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. GERMANY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 289. GERMANY COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. GERMANY COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. FRANCE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. FRANCE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 294. FRANCE COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 295. FRANCE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. FRANCE COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. FRANCE COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. FRANCE COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. RUSSIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 300. RUSSIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 301. RUSSIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 302. RUSSIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 303. RUSSIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. RUSSIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. RUSSIA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 306. RUSSIA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 307. ITALY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. ITALY COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. ITALY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 310. ITALY COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 311. ITALY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. ITALY COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. ITALY COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 314. ITALY COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 315. SPAIN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. SPAIN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. SPAIN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 318. SPAIN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 319. SPAIN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 320. SPAIN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 321. SPAIN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. SPAIN COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. CHINA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. CHINA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. CHINA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 326. CHINA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 327. CHINA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. CHINA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. CHINA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. CHINA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. INDIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 332. INDIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 333. INDIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 334. INDIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 335. INDIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. INDIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. INDIA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 338. INDIA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 339. JAPAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. JAPAN COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. JAPAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 342. JAPAN COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 343. JAPAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. JAPAN COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 345. JAPAN COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 346. JAPAN COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 348. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2018-2024 (USD MILLION)
  • TABLE 350. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY REAL TIME PCR TEST, 2025-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 352. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 354. AUSTRALIA COVID-19 TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA COVID-19 TESTING MARKET